SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagyXin-yu Zhao, Shuang-shuang Li, Ying-xin He, Li-jie Yan, Fu Lv, Qi-meng Liang, Yu-hui Gan, Li-pei Han, Hong-de Xu, Yong-chun Li, Yuan-yuan Qi
24 July 2023
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomesMay Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J Fritzler, Katherine A Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J Wallace, David Alan IsenbergSee the full list of authors
21 April 2023
Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupusDionysis Nikolopoulos, Theodora Manolakou, Alexia Polissidis, Anastasia Filia, George Bertsias, Yassemi Koutmani, Dimitrios T Boumpas
10 March 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, Vera Golder, Raj Tummala
23 January 2023
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling studyJingru Tian, Dingyao Zhang, Xu Yao, Yaqing Huang, Qianjin Lu
14 October 2022
3D genome alterations in T cells associated with disease activity of systemic lupus erythematosusMing Zhao, Delong Feng, Longyuan Hu, Lin Liu, Jiali Wu, Zhi Hu, Haojun Long, Qiqi Kuang, Lianlian Ouyang, Qianjin Lu
1 September 2022
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reportsMichelle Petri, Helain Landy, Megan E B Clowse, Kim Gemzoe, Munther Khamashta, Milena Kurtinecz, Roger A Levy, Andrew Liu, Rebecca Marino, Paige Meizlik, Jeanne M Pimenta, Kelsey Sumner, Hugh Tilson, Mary Beth Connolly, Keele WurstSee the full list of authors
5 October 2022
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trialJens Y Humrich, Patrice Cacoub, Michelle Rosenzwajg, Fabien Pitoiset, Hang Phuong PHAM, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S Smolen, George Tsokos, David Klatzmann
16 August 2022
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-αAlexis Mathian, Paul Breillat, Karim Dorgham, Paul Bastard, Caroline Charre, Raphael Lhote, Paul Quentric, Quentin Moyon, Alice-Andrée Mariaggi, Suzanne Mouries-Martin, Clara Mellot, François Anna, Julien Haroche, Fleur Cohen-Aubart, Delphine SterlinSee the full list of authors
16 August 2022
Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IVMaddalena Maria Bolognesi, Giulia Capitoli, Stefania Galimberti, Giorgio Cattoretti, Ingeborg Bajema, Jan A Bruijn, H Terence Cook, Laure-Helene Noel, Fabio Pagni, Franco Ferrario, Maria Wester Trejo, Vincenzo L'Imperio
8 August 2022